GlassScriptPhysician profile
Sharone Sabo
NPI 1710440615
$3,266.85
in general payments reported to CMS, 2019-2025
22 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $768 · 2023: $298 · 2024: $932 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.05 |
| Education | $264.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $688.10 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Sun Pharmaceutical Industries INC. | $536.12 | 2021-2025 | Ilumya |
| Abbvie INC. | $391.68 | 2021-2025 | |
| Genzyme Corporation | $299.95 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $210.05 | 2024-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $206.82 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $191.40 | 2021-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Incyte Corporation | $117.75 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $96.31 | 2024-2025 | Ebglyss, Taltz |
| Leo Pharma INC. | $64.48 | 2022-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $52.95 | 2024 | |
| Pfizer INC. | $51.62 | 2021-2022 | |
| Dermavant Sciences, INC. | $50.22 | 2024 | Vtama |
| Botanix Sb INC | $40.38 | 2025 | Sofdra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $26.50 | 2021 | |
| Organon LLC | $24.68 | 2025 | |
| Organogenesis INC. | $22.95 | 2025 | Affinity |
| Almirall LLC | $20.38 | 2025 | Klisyri |
| Verrica Pharmaceuticals INC. | $17.91 | 2024 | Ycanth |
| Biofrontera INC. | $17.04 | 2022 | |
| Amgen INC. | $14.56 | 2025 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharone Sabo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.